Novartis announces positive results from final Phase III omalizumab registration study in severe form of chronic skin disease CSU
Novartis announced today new results from the Phase III ASTERIA I study showing omalizumab was effective and safe in the treatment of chronic spontaneous urticaria (CSU)[1], a chronic and debilitating form of hives. ASTERIA I […]